Table 4. Antimicrobial resistance levels of Acinetobacter baumannii and Pseudomonas aeruginosa isolates.

A) Acinetobacter baumannii
		N	Antibiotic resistance levels
			SAM		CTX		CAZ		FEP		IPM		MEM		AMK		GEN		CIP		TMP/SMX
			%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P	%	P
M+S+I	P1	189	65	<0.05	91	0.06	85	<0.05	85	<0.05	63	<0.05	61	<0.05	84	<0.05	78	NS	89	NS	86	NS
	P2	414	91		97		93		93		90		88		69		72		93		90
	O	603	83		95		91		91		81		80		74		74		92		89
M	P1	100	61	<0.05	87	NS	81	NS	81	NS	61	<0.05	61	<0.05	81	<0.05	78	NS	87	NS	84	NS
	P2	147	89		92		88		88		86		78		59		71		88		84
	O	247	78		90		85		85		76		72		68		74		88		84
S	P1	33	68	<0.05	88	NS	82	<0.05	82	0.08	63	<0.05	64	<0.05	82	NS	73	NS	88	NS	91	NS
	P2	94	91		95		94		93		87		90		67		76		94		89
	O	127	86		93		91		90		81		83		71		75		93		90
I	P1	56	61	<0.05	100	NS	95	NS	93	NS	67	<0.05	71	<0.05	91	<0.05	80	<0.05	93	NS	86	<0.05
	P2	173	91		99		96		98		95		95		74		72		97		96
	O	229	83		99		96		97		88		89		78		76		95		93
P1	PM+S/I			NS		<0.05		<0.05		<0.05		NS		NS		NS		NS		NS		NS
P2	PM+S/I			NS		<0.05		<0.05		<0.05		<0.05		<0.05		<0.05		NS		<0.05		<0.05
O	PM+S/I			NS		<0.05		<0.05		<0.05		<0.05		<0.05		<0.05		NS		<0.05		<0.05

In the Table are only reported significant differences (P <0.05), as well as those P-values ≤0.09.

In Period 2 susceptibility to colistin was established in 20 A. baummanni and 31 P. aeruginosa isolates, and that of tigecycline was established in 37 A. baumanni isolates, all being susceptible.

M, medicine; S, surgery; I, intensive care unit; P1, Period 1 (2009 - 2010); P2, Period 2 (2012 - 2014); O, overall; SAM, ampicillin-sulbactam; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; CIP: ciprofloxacin; TMP/SMX, trimethoprim-sulfamethoxazole; NS, non significant; ATM, aztreonam; TZP, piperacillin-tazobactam.